by Louise Adams | 1 May 2025 | Blog
I’ve emerged from the isolation tank, prepared to dive back in to our final chapter on The Lancet’s PR piece. This is Part 4 of the series: click on the links to read Part 1, Part 2, and Part 3. It’s a long read, and full of truly awful fat phobia:...
by Louise Adams | 30 Apr 2025 | Blog
Thanks for bearing with me as we trawl through the seemingly endless Lancet Commission on ‘clinical o*esity’. Click here to read Parts 1 and 2.Please be advised that the following post contains multiple meat-puns, which may be triggering to vegetarians/the...
by Louise Adams | 17 Feb 2025 | Blog
Welcome to Part 2 of our probe into the Lancet paper defining ‘clinical o*esity.’ If you haven’t read Part 1 you can do so here – it’ll make much more sense. For more than two decades I’ve been wading through the stench-swamp of o*esity research, unmasking...
by Louise Adams | 30 Jan 2025 | Blog
Since the 1990’s, the weight loss industry has been pushing to have ‘o*esity*’ classified as a disease. This is the Holy Grail for pharmaceutical companies, because disease status opens the door to government and insurance subsidies, ensuring a...
by Louise Adams | 13 Jan 2025 | Blog
I’m back with some sterling examples of how Novo Nordisk genuinely care about human health. If you haven’t already, please read Parts 1 and 2 of Risky Business, for a deep dive into Novo’s clever glow-up of their weight loss drugs as cardiovascular...
by Louise Adams | 6 Jan 2025 | Blog
The current hype about weight loss drugs is inescapable, and media coverage is worryingly – and consistently – uncritical. I recently came across this article on the ABC news website: ‘Doctors weigh societal costs of using obesity drugs to treat obesity...
